Publications by authors named "I Plaza Macias"
Background: The combination chemotherapy i.v. 5-fluorouracil (5-FU), irinotecan, and aflibercept (FOLFIRI-A) is a standard second-line treatment of metastatic colorectal cancer (mCRC).
View Article and Find Full Text PDFBackground: Highlighting the identified gaps in evidence-based research concerning advanced esophageal cancer (EC) treatment and care, this review evaluates the efficacy and safety of anticancer drugs compared to supportive care for advanced EC patients, aiming to assess the appropriateness of usual treatments and identify the gaps that need to be filled with primary research.
Methods: We searched (May 2022) MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Epistemonikos, and trial registries (ClinicalTrials.gov and PROSPERO) for randomised controlled trials (RCTs) comparing anticancer drugs (chemotherapy, immunotherapy, or biological/targeted therapy) with supportive care in advanced EC.
Qualitative alterations in type I collagen due to pathogenic variants in the COL1A1 or COL1A2 genes, result in moderate and severe Osteogenesis Imperfecta (OI), a rare disease characterized by bone fragility. The TGF-β signaling pathway is overactive in OI patients and certain OI mouse models, and inhibition of TGF-β through anti-TGF-β monoclonal antibody therapy in phase I clinical trials in OI adults is rendering encouraging results. However, the impact of TGF-β inhibition on osteogenic differentiation of mesenchymal stem cells from OI patients (OI-MSCs) is unknown.
View Article and Find Full Text PDFAim: To assess the appropriateness of systemic oncological treatments (SOT) provided to patients diagnosed with advanced esophageal cancer (EC) across a group of participating hospitals.
Methods: Multicenter, retrospective cohort study in five Spanish hospitals including newly confirmed advanced EC cases between July 1, 2014, and June 30, 2016, with a 5-year follow-up.
Results: We identified 157 patients fulfilling the inclusion criteria (median age: 65 years, 85.
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
Clin Transl Oncol
July 2024
Article Synopsis
- The study investigates the effectiveness and tolerability of different chemotherapy regimens (FOLFOX, CAPOX, CP, and FP) for treating HER2-negative advanced esophagogastric cancer, using data from the AGAMENON-SEOM Spanish registry between 2008 and 2021.
- Results indicate that FOLFOX significantly improves progression-free survival (PFS) compared to the CP regimen, although treatment durations were similar among all groups.
- Adverse effects varied by regimen, with higher rates of fatigue and neuropathy seen in FOLFOX, while CP showed notable incidences of hand-foot syndrome and thromboembolic events.